US 11234939
Dosage forms comprising a plasma kallikrein inhibitor
granted A61KA61K31/00A61K31/444
Quick answer
US patent 11234939 (Dosage forms comprising a plasma kallikrein inhibitor) held by KalVista Pharmaceuticals Limited expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- KalVista Pharmaceuticals Limited
- Grant date
- Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 53
- CPC classes
- A61K, A61K31/00, A61K31/444, A61K45/06, A61K9/0053